Quarterly ResultMay 6, 2026, 06:08 AM
Ultragenyx Q1 Revenue $136M, Net Loss $(185)M
AI Summary
Ultragenyx Pharmaceutical Inc. reported a net loss of $(185) million for the first quarter of 2026, an increase from $(151) million in the prior year, on total revenues of $136 million, down from $139 million. The company experienced increased operating expenses, particularly in research and development, and a significant decrease in cash and cash equivalents. Ultragenyx is pursuing a restructuring plan announced in February 2026 and aims for profitability in 2027.
Key Highlights
- Total revenues for Q1 2026 decreased to $136 million from $139 million year-over-year.
- Net loss for Q1 2026 increased to $(185) million from $(151) million in Q1 2025.
- Net loss per share was $(1.84) in Q1 2026, compared to $(1.57) in Q1 2025.
- Research and development expenses rose to $187 million from $166 million year-over-year.
- Cash and cash equivalents decreased to $175 million as of March 31, 2026, from $421 million.
- Crysvita product sales declined to $46 million from $55 million in the prior year.
- Evkeeza product sales increased to $18 million from $11 million year-over-year.
- The company aims to achieve profitability in 2027.
Price Impact
More from RARE